Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
EMZ702 · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| EMZ702 | DRUG | - |
Inclusion Criteria: * Hepatitis C virus (HCV) genotype 1 * Previous therapy with pegylated interferon and ribavirin * Documented previous treatment failure Exclusion Criteria: * Hepatic dysfunction * Coinfection with hepatitis B or HIV * Other unrelated liver diseases * Liver cancer
EMZ702 is an investigational small molecule being studied for the treatment of chronic Hepatitis C. It was evaluated in a Phase 1 clinical trial in patients with chronic Hepatitis C who were non-responders to prior therapy. The drug is still in clinical development and is not approved.
EMZ702 is being developed by Opko Health Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol OPK. The company conducted a Phase 1 clinical trial of EMZ702 in patients with chronic Hepatitis C.
EMZ702 is in Phase 1 clinical development. A Phase 1 trial of EMZ702 in chronic Hepatitis C has been completed. The drug is investigational and has not been approved for any use.
EMZ702 has been studied in one clinical trial, registered as NCT00230854. This Phase 1 study, titled 'Study in Non-responder Hepatitis C Genotype 1 Patients With EMZ702, Pegylated Interferon and Ribavirin', was conducted in Canada and enrolled 28 patients with chronic Hepatitis C. The trial has been completed.
EMZ702 is a small molecule therapeutic being developed for chronic Hepatitis C. Its specific molecular target has not been disclosed in available information, so its mechanism of action is not described here.